10-K: KORU Medical Systems Reports Strong Revenue Growth in 2024 10-K Filing

KORU Medical Systems reports an 18% increase in net revenues for the year ended December 31, 2024, driven by growth in core domestic and international businesses and novel therapies.

Summary

• KORU Medical Systems, Inc. filed its 10-K report for the fiscal year ended December 31, 2024.
• The company develops, manufactures, and commercializes innovative patient-centric large volume subcutaneous infusion solutions.
• KORU Medical's revenues are derived from domestic core, international core, and novel therapies businesses.
• Net revenues for 2024 reached $33.6 million, an 18% increase compared to $28.5 million in 2023.
• Domestic core revenue grew by 12.3%, international core by 31.5%, and novel therapies by 61.9%.
• Gross profit for 2024 was $21.3 million, a 27.7% increase from the previous year, with a gross margin of 63.4%.
• Operating expenses for 2024 were $27.8 million, slightly up from $27.0 million in 2023.
• The company reported a net loss of $6.1 million for 2024, a significant decrease from the $13.7 million loss in 2023.
• As of December 31, 2024, the company's cash and cash equivalents totaled $9.6 million.
• The company expects its cash on hand and cash flows from operations will be sufficient to meet its requirements at least through the next twelve months.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and improved profitability, but also acknowledges existing risks and challenges.

Positives

• Significant revenue growth driven by core businesses and novel therapies.
• Improved gross profit and gross margin due to increased manufacturing productivity and better product mix.
• Substantial decrease in net loss compared to the previous year.
• The company believes that its cash on hand and cash flows from operations will be sufficient to meet its requirements at least through the next twelve months.

Negatives

• The company reported a net loss of $6.1 million for 2024.
• Operating expenses increased slightly compared to the previous year.
• The company is dependent on a small number of distributors, with one U.S. distributor contributing 35% of net revenues.

Risks

• The company faces risks related to introducing new products and keeping pace with technological advances.
• The business depends on an adequate supply of drugs to be administered by its products.
• Compliance with EU MDR regulations by December 2028 will require significant investment.
• Interruption of manufacturing or contract manufacturing operations could adversely affect the business.
• The company operates in a highly competitive industry.
• Healthcare policy changes and cost-containment measures could result in downward pricing pressure.
• The company may need additional funding in the future.
• The company is subject to foreign currency exchange risk.
• Cybersecurity breaches and data leakage pose risks to the company's information technology systems.

Future Outlook

The company intends to make additional investments in research and development for a next-generation infusion pump and consumable system as well as for future innovation. The company expects that its cash on hand and cash flows from operations will be sufficient to meet its requirements at least through the next twelve months. Continued execution on our longer-term strategic plan may require the Company to draw on our credit facility, take on additional debt, raise capital through issuance of equity, or a combination.

Management Comments

• Our mission is to improve the quality of life of patients around the world by delivering innovative, effective, and easy-to-use drug delivery systems that can be used at home or alternate site settings, for patient self-administration of drug therapy.
• Our goal is to strengthen our position as a leading provider of large-volume subcutaneous infusion systems (10ml) for self-administration in the home and for administration by healthcare professionals in infusion centers.

Industry Context

The company operates in the medical device industry, specifically focusing on infusion systems. The report highlights trends such as increasing diagnoses of Primary Immunodeficiency Diseases (PIDD), expansion of on-label SCIg indications, and growth in SCIg treatment options.

Comparison to Industry Standards

• The FREEDOM System competes with electronic (volumetric) pumps, elastomeric (infuser) pumps, and fully mechanical pumps.
• The company notes that no single technological approach will meet the needs of all or even a majority of drugs.
• For drugs requiring infusion volumes over 3 ml, the segment most similar to the SCIg drugs currently delivered by the FREEDOM System, the most relevant approaches include mechanical pumps, on-body wearable devices, and simple electronic pumps.

Corporate Governance

Legal Proceedings

• In the ordinary course of our business, we may be subject to various claims, pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business.
• We are not aware of any current material pending legal proceedings to which we are a party or of which any of our properties is the subject.

Stakeholder Impact

• The company's performance impacts shareholders through stock value and potential dividends.
• Employees are affected by compensation, benefits, and training opportunities.
• Customers benefit from innovative and effective drug delivery systems.
• Suppliers are impacted by the company's manufacturing and sourcing activities.

Next Steps

• The company intends to partner with biopharmaceutical manufacturers during clinical development.
• The company intends to commercialize its products for use with new drugs, working with pharmaceutical partners, distributors, and specialty pharmacy partners.

Key Dates